Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression

Curr Med Res Opin. 2025 Sep 15:1-9. doi: 10.1080/03007995.2025.2555483. Online ahead of print. ABSTRACT OBJECTIVE: ESCAPE-TRD, a randomized phase 3b trial, compares the efficacy and safety of esketamine nasal spray (NS) and extended-release (XR) quetiapine, both in...